Andere Sprachen Kane Biotech Inc.

Aktien

A2DNC4

CA4838092084

KNE

Markt geschlossen - Toronto S.E. Andere Börsenplätze 21:44:55 26.04.2024			% 5 Tage	% 1. Jan.
0,125 ^CAD	-3,85 %		-7,41 %	+56,25 %

18.04.	Transcript : Kane Biotech Inc. - Special Call
15.04.	Dechra Veterinary Products, Inc. hat die Übernahme von 66,66% der Anteile an STEM Animal Health Inc. von Kane Biotech Inc. (TSXV:KNE) abgeschlossen.	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Kane Biotech to Host Investor Webinar	16.04.
Kane Biotech Up 12% After Reporting Closing of STEM Animal Health Sale	15.04.
Kane Biotech Announces Closing of the Sale of STEM Animal Health to Dechra Veterinary Products	15.04.
Dechra Veterinary Products, Inc. completed the acquisition of 66.66% stake in STEM Animal Health Inc. from Kane Biotech Inc..	15.04.
Kane Biotech Agrees to Sell its Interest in STEM Animal Health for US$8 Million	11.04.
Canadian Investment Regulatory Organization Trade Resumption - KNE	11.04.
Kane Biotech Announces Agreement in Principle for the Sale of its Interest in STEM Animal Health	11.04.
Canadian Investment Regulatory Organization Trading Halt - KNE	11.04.
Kane Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26.03.
Kane Biotech Brief: Says otal revenue for the three months ended December 31, 2023 was $764,997	26.03.
Kane Biotech Announces Fourth Quarter and Full Year 2023 Financial Results	26.03.
Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health	20.03.
Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health	20.03.
Kane Biotech to Release Fourth Quarter and Full Year 2023 Financial Results on March 26, 2024 – Conference Call to Follow	19.03.
Kane Biotech to Release Fourth Quarter and Full Year 2023 Financial Results on March 26, 2024 – Conference Call to Follow	19.03.
Kane Biotech Receives Bioscience Association Manitoba Company of the Year Award	08.03.
Dr. Robert Huizinga Elected to the Kane Biotech Board and Appointed Executive Chair	22.02.
Dr. Robert Huizinga Elected to the Kane Biotech Board and Appointed Executive Chair	22.02.
Kane Biotech Inc. Appoints Dr. Robert Huizinga as Director and Executive Chair	22.02.
Kane Biotech Inc. Files New Patent on Revyvetm Antimicrobial Wound Gel Spray	31.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Kane Biotech Inc.

Aktien

A2DNC4

CA4838092084

KNE

Andere Sprachen

Filter